Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab plus AMG 404 in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
NL-OMON55298Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab and zeluvalimab in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and Treatment-emergent adverse events. Started Apr 2021; status: completed.
02
Drugs
blinatumomabzeluvalimab
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON55298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55298.